Compare LIVE & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIVE | CTSO |
|---|---|---|
| Founded | 1968 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 45.7M |
| IPO Year | 1998 | 2008 |
| Metric | LIVE | CTSO |
|---|---|---|
| Price | $12.20 | $0.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 5.2K | ★ 67.9K |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 158.14 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | N/A | $8.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $6.25 | $0.60 |
| 52 Week High | $25.88 | $1.39 |
| Indicator | LIVE | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 26.35 | 62.95 |
| Support Level | $9.05 | $0.61 |
| Resistance Level | $18.99 | $0.84 |
| Average True Range (ATR) | 1.13 | 0.04 |
| MACD | -0.45 | 0.01 |
| Stochastic Oscillator | 3.77 | 77.89 |
Live Ventures Inc is a holding company of diversified businesses. It acquires and operates companies with a history of earnings power across five segments: Retail-Entertainment, Retail-Flooring, Flooring Manufacturing, Steel Manufacturing, and Corporate & Other. Retail-Entertainment offers new and pre-owned movies, video games, music, books, comics and collectibles through an integrated buy-sell-trade model. Retail-Flooring is a retailer and installer of flooring, carpeting, and countertops, serving consumers, builders, and contractors. Flooring Manufacturing produces and distributes carpet and hard-surface flooring. Steel Manufacturing engages in steel production and fabrication, generating the majority of revenue. Corporate & Other covers corporate costs and legacy products and services.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.